Hidden TB reservoirs: lymph nodes fuel relapse

Tuberculosis can return after what appears to be successful treatment, but exactly where the returning bacteria come from has been hard to pin down. In work led by Philana Ling Lin, researchers used a macaque model to study how Mycobacterium tuberculosis (Mtb) spreads and reappears after treatment. The team focused on sites in the chest that can harbor bacteria during and after therapy. Their findings show that when disease relapses, the Mtb population that seeds new disease does not come from a single place. Instead, dissemination during relapse can originate from both the lung tissue and the thoracic lymph nodes. This highlights thoracic lymph nodes as an important reservoir where bacteria can survive treatment and later reseed infection, changing how we think about the physical locations that matter for preventing relapse.

To follow individual bacterial populations and the spots they occupied, the researchers matched bar-coded Mtb and serial PET CT scans over time. The bar-coded Mtb approach lets scientists tag different bacterial clones so they can be identified later, and serial PET CT provides repeated images that show where inflammation and bacterial activity persist in the chest. By combining these two tools, the team could directly link specific persistent sites seen on imaging with the bar-coded bacteria recovered during relapse. A key result was that not every site showing persistent Mtb growth after drug treatment went on to cause dissemination and relapse. Some lesions remained localized without seeding new disease, while both lung lesions and thoracic lymph node lesions were shown to be sources of spreading bacteria in other cases. These observations point to a nuanced relationship between visible persistent disease on PET CT and the actual risk of relapse.

The study’s results matter because they change how clinicians and researchers should think about residual disease after treatment. Identifying thoracic lymph nodes as a reservoir suggests that therapies and monitoring strategies must consider lymphatic sites, not just obvious lung lesions. The finding that not all persistent sites are capable of dissemination also suggests that imaging alone may overestimate relapse risk unless paired with ways to identify which lesions harbor transmissible bacteria. Using bar-coded Mtb together with serial PET CT offers a method to distinguish dangerous reservoirs from inert residual lesions, and could guide future work to target the anatomical locations most likely to cause relapse. Overall, the work underscores the complexity of drug treatment outcomes and points toward more precise ways to prevent tuberculosis from coming back.